This review discusses the pathophysiology of hypertensive cardiac remodeling and the impact of lifestyle modifications and antihypertensive drugs on hypertensive heart disease.
Do lifestyle modifications and antihypertensive drug treatments affect the development, progression, and regression of hypertensive heart disease?
This review summarizes the pathophysiology of hypertensive heart disease and the role of lifestyle and pharmacological interventions in regressing myocardial hypertrophy and reducing cardiovascular risk.
Target-organ protection in hypertensive patients has become increasingly important. This review will focus on hypertensive heart disease that is mainly characterized by myocardial hypertrophy and increased interstitial fibrosis. Cardiac remodeling develops as an adaptive response but actually represents a powerful independent risk factor for cardiovascular morbidity and mortality. The review will begin with a brief discussion on the complex pathophysiology of hypertensive cardiac remodeling and its clinical consequences. The effects of nonpharmacologic and pharmacologic antihypertensive treatments on the development and progression of hypertensive heart disease are presented. Finally, the impact of the regression of myocardial hypertrophy and fibrosis on cardiac function and cardiovascular risk are discussed.
Anna Maria Grandi (Thu,) conducted a review in Hypertensive heart disease. Lifestyle modifications and antihypertensive drug treatment was evaluated. This review discusses the pathophysiology of hypertensive cardiac remodeling and the impact of lifestyle modifications and antihypertensive drugs on hypertensive heart disease.